NanoViricides is a clinical-stage biopharmaceutical company that develops broad-spectrum antiviral therapies. The company's platform technology, termed nanoviricides, creates nanomedicines that mimic host cell-surface receptors to bind, engulf, and destroy virus particles, aiming to overcome viral mutation and drug resistance. NanoViricides' lead drug candidate, NV-387, is an oral antiviral entering Phase II clinical trials for Mpox and Ebola, with planned development for Measles and acute respiratory infections including Influenza, RSV, and Coronaviruses. The company is also developing NV-HHV-1, a topical treatment targeting Shingles and other herpesviruses. NanoViricides focuses initial clinical development on orphan and rare disease indications to accelerate regulatory pathways before advancing into broader respiratory markets, supported by its internal cGMP manufacturing facility. As a pre-commercial company without approved products, NanoViricides plans to monetize its drug candidates through out-licensing agreements, biopharmaceutical partnerships, and government biodefense contracts.